There are several ongoing clinical trials on the efficacy of Olaparib, Rucaparib, Niraparib, Veliparib, and, more recently, Talazoparib in overcoming PARP1-mediated resistance in hematological malignancies [80]. This evidence concerns the gene PARP1 and hematologic disorder.